Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy

Clinics

Volumn 67, Issue 9, 2012, Pages 1047-1052

  Casella, Antonio Marcelo Barbante ^a   Berbel, Rodrigo Fabri ^a   Bressanim, Gláucio Luciano ^b   Malaguido, Marcus Rudolph ^a   Cardillo, José Augusto ^c  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b Department of Ophthalmology   (Brazil)

^c Hospital de Olhos de Araraquara   (Brazil)

Author keywords

Central Serous Chorioretinopathy; Helicobacter Pylori; Macula; Risk Factors; Treatment

Indexed keywords

ADULT; ARTICLE; CENTRAL SEROUS RETINOPATHY; CHRONIC DISEASE; DRUG EFFECT; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; MICROBIOLOGY; MIDDLE AGED; RETINA DETACHMENT; RISK FACTOR; STOMACH DISEASE; TIME; TREATMENT OUTCOME;

ADULT; CENTRAL SEROUS CHORIORETINOPATHY; CHRONIC DISEASE; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; RETINAL DETACHMENT; RISK FACTORS; STOMACH DISEASES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867187904     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(09)11     Document Type: Article

References (29)

1. Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA, Fisher YL, et al. Systemic and ocular findings in central serous chorioretinopathy. Am J Ophthalmol. 1999;128(1):63-8, http://dx.doi.org/10.1016/S0002-9394(99)00075-6.
2. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004;111(20):244-9, http://dx.doi.org/10.1016/j.ophtha.2003.09.024.
3. Guyer DR, Gagroudas ES. Central Serous Chorioretinopathy. In: Albert DM, Jakobiec FA. Principles and Practice of Ophthalmology. Philadelphia: Saunders, 1994;818-25.
4. Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996;103(12):2070-80.
5. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot Study. Retina. 2003;23(3):288-98, http://dx.doi.org/10.1097/00006982-200306000-00002.
6. Carvalho-Recchia CA, Yannuzzi LA, Negrão S, Spaide RF, Freund KB, Rodriguez-Coleman H, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002;109(1):1834-7, http:// dx.doi.org/10.1016/S0161-6420(02)01117-X.
7. Koyama M, Mizota A, Igarashi Y, Adachi-Usami E. Seventeen cases of central serous chorioretinopathy associated with systemic corticosteroid therapy. Ophthalmologica. 2004;218(2):107-10, http://dx.doi.org/ 10.1159/000076145.
8. Michael JC, Pak J, Pulido J, de Venecia G. Central serous chorioretinopathy associated with administration of sympathomimetic agents. Am J Ophthalmol. 2003;136(1):182-5, http://dx.doi.org/10.1016/S0002-9394(03)00076-X.
9. Giusti C. Central serous chorioretinopathy: a new extragastric manifestation of Helicobacter pylori? Analysis of a clinical case. Clin Ter. 2001;152(6):393-7.
10. Mauget-Faÿsse M, Kodjikian L, Quaranta M, Ben Ezra D, Trepsat C, Mion F, et al. Rô le de l'Helicobacter pylori dans la choriorétinopathie séreuse centrale et l'épithéliopathie rétinienne diffuse. Résultats de la premiére étude prospective pilote. J Fr Ophtalmol. 2002;25(10):1021-5.
11. Ahnoux-Zabsonre A, Quaranta M, Mauget-Faÿsse M. Prévalence de l'Helicobacter pylori dans la choriorétinopathie séreuse centrale et l'épithéliopathie rétinienne diffuse. J Fr Ophtalmol. 2004;27(10):1129-33, http://dx.doi.org/10.1016/S0181-5512(04)96281-X.
12. Asensio-Sánchez VM, Rodri{dotless}́guez-Delgado B, Garci{dotless}́a-Herrero E, Cabo-Vaquera V, Garci{dotless}́a-Loygorri C. Coriorretinopati{dotless}́a serosa central como manifestación extradigestiva de infección gástrica por Helicobacter pylori. Arch Soc Esp Oftalmol. 2008;83(3):177-82.
13. Giusti C. Association of Helicobacter pylori with central serous chorioretinopathy: hypotheses regarding pathogenesis. Med Hypotheses. 2004;63(3):524-7, http://dx.doi.org/10.1016/j.mehy.2004.02.020.
14. Cotticelli L, Borrelli M, D'Alessio AC, Menzione M, Villani A, Piccolo G, et al. Central serous chorioretinopathy and Helicobacter pylori. European journal of ophthalmology. 2006;16(2):274-8.
15. Misiuk-Hojło M, Michałowska M, Turno-Krecicka A. Helicobacter pylori--a risk factor for the development of the central serous chorioretinopathy. Klin Oczna. 2009;111(1-3):30-2.
16. Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L, Rafeey M, Ghorbanihaghjo A. The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis. 2011;17:99-103.
17. Ogata SK, Kawakami E, Patri{dotless}́cio FRS, Pedroso MZ, Santos AM. Evolution of invasive and non-invasive methods for the diagnosis of Helicobacter pylori in symptomatic children and adolescents. São Paulo Med J. 2001;119(2):67-71, http://dx.doi.org/10.1590/S1516-31802001000200006.
18. Santos IS, Boccio J, Santos AS, Valle NC, Halal CS, Bachilli MC, et al. Prevalence of Helicobacter pylori infection and associated factors among adults in Southern Brazil: a population-based cross-sectional study. BMC Public Health. 2005;5:118, http://dx.doi.org/10.1186/1471-2458-5-118.
19. Zaterka S, Eisig JN, Chinzon D, Rothstein W. Factors related to Helicobacter pylori prevalence in an adult population in Brazil. Helicobacter. 2007;12(1):82-8.
20. MitchellHM. The epidemiology of Helicobacter pylori. Curr Top Microbiol Immunol. 1999;241:11-30, http://dx.doi.org/10.1007/978-3-642-60013-5_2.
21. D'Elios MM, Andersen LP. Helicobacter pylori: Inflammation, Immunity, and Vaccines. Helicobacter. 2007;12(Suppl.1):15-9, http:// dx.doi.org/10.1111/j.1523-5378.2007.00530.x.
22. Maeda S, Mentis AF. Pathogenesis of Helicobacter pylori Infection. Helicobacter. 2007;12 (Suppl.1):10-4.
23. Bohr URM, Annibale B, Franceschi F, Roccarina D, Gasbarrini A. Extragastric Manifestations of Helicobacter pylori Infection-Other Helicobacters. Helicobacter. 2007;12(Suppl. 1):45-53.
24. Whittle BJR, Morschl E, Pozsár J, Moran AP, László F. Helicobacter pylori lipopolysaccharide provokes iNOS-mediated acute systemic microvascular inflammatory responses in rat cardiac, hepatic, renal and pulmonary tissues. J Physiol Paris. 2001;95(1-6):257-9, http:// dx.doi.org/10.1016/S0928-4257(01)00035-3.
25. Giusti C, Mauget-Faÿ sse M. Helicobacter pylori and idiopathic central serous chorioretinopathy. Swiss Med Wkly. 2004;134(27-28):395-8.
26. Ushiama H, Echizen H, Nachi S, Ohnishi A. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin Pharmacol Ther. 2002;72(1):33-43, http://dx.doi.org/10.1067/mcp.2002.125559.
27. Mansuetta CC, Mason JO 3rd, Swanner J, Feist RM, White MF Jr, Thomley ML, et al. An association between central serous chorioretinopathy and gastroesophageal reflux disease. Am J Ophthalmol. 2004;137(6):1096-100, http://dx.doi.org/10.1016/j.ajo.2004.01.054.
28. Aggio FB, Roisman L, Melo GB, Lavinsky D, Cardillo JA, Farah ME. Clinical factors reralted to the visual outcome in central serous choriorretinopathy. Retina. 2010;30(7):128-34.
29. Abreu R, Nadal J, Abreu P. Helicobacter pylori and central serous chorioretinopathy. Arch Soc Esp Oftalmol. 2008;83(11):637-8.